**Comprehensive Medical Report**

**Patient Information:**

* Age: 49
* Sex: Not specified
* ECOG Performance Status: 1

**Medical History:**

* Muscle Invasive Bladder Cancer (MIBC)
* Recent transurethral resection of bladder tumor (TURBT) to remove the tumor
* No prior chemotherapy or radiation therapy
* FGFR3 point mutation identified
* Chronic Kidney Disease (CKD) stage 2 with:
	+ eGFR: 60-89 mL/min
	+ Creatinine levels: 1.5-1.8 mg/dL
* No prior surgeries or conditions that may affect eligibility for clinical trials
* No history of organ transplants, HIV, or hepatitis B/C infection

**Symptoms:**

* Hematuria (visible blood in urine)
* Urinary frequency
* Mild pelvic pain

**Current Medications:**

* None mentioned

**Treatment Goals:**

* Patient is seeking an immunotherapy or precision medicine approach in a clinical trial
* Willing to consider combination therapy trials that pair an FGFR inhibitor with an immunotherapy agent
* Also open to single-agent precision medicine approaches

**Clinical Trial Eligibility:**

* Seeking trials that focus on MIBC with FGFR3 point mutations
* Interested in trials that investigate FGFR inhibitors, checkpoint inhibitors, or other immunotherapies
* Trials should be suitable for patients with CKD stage 2 and mild pelvic pain

**Relevant Laboratory Results:**

* eGFR: 60-89 mL/min
* Creatinine levels: 1.5-1.8 mg/dL
* FGFR3 point mutation identified

**Other Relevant Information:**

* Patient is closely monitored for kidney function due to CKD stage 2
* Patient's symptoms are manageable but present

**Recommendations:**

* Consider enrolling patient in clinical trials that investigate FGFR inhibitors or combination therapies with immunotherapy agents
* Monitor patient's kidney function closely throughout the trial
* Assess patient's symptoms and quality of life regularly to ensure trial tolerability

This comprehensive medical report provides a detailed summary of the patient's condition, medical history, and treatment goals. It will serve as a valuable resource for healthcare professionals to identify suitable clinical trials for the patient.